Skip to content

Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis

Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01731262
Enrollment
78
Registered
2012-11-21
Start date
2012-11-30
Completion date
2013-01-31
Last updated
2012-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid, Neovascularization, Pathologic, Synovitis

Keywords

Arthritis, Rheumatoid, Sonic hedgehog protein, human, Neovascularization, Pathologic, Synovitis

Brief summary

Rheumatoid arthritis(RA) with a high incidence and high morbidity, the pathogenesis has not been fully elucidated. Fibroblast-like synovial cells excessive proliferation and synovial angiogenesis is the most important cause of RA synovitis and joint destruction. Our study was to find the role of Sonic Hedgehog(SHH) pathway in regulating proliferation of fibroblast-like synovial cells and modulating excess angiogenesis of synovial tissue.

Detailed description

4ml blood from active RA patients(n=35) and healthy volunteers (n=35) will be collected * peripheral blood mononuclear cells will be detached * messenger ribonucleic acid expression of Sonic Hedgehog pathway associated factors in both groups will be detected Synovial tissues from 4 RA patients and 4 patients with traumatic or meniscal injury who need to carry out knee joint replacement operation will be collected * inflammatory feature of synovial tissue will be observed * the expression of Shh, Ptch1, Gli1 and Smo in synovial tissue will be detected by immunohistochemistry assay * fibroblast-like synoviocytes will be cultured from synovial tissue of RA patients

Interventions

None listed

Sponsors

National Natural Science Foundation of China
CollaboratorOTHER_GOV
Third Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* definitely diagnosed * the disease is active (DAS28\>3.2)

Exclusion criteria

* combined with severe organ dysfunction * combined with other rheumatic diseases

Design outcomes

Primary

MeasureTime frame
mRNA expression1 day (December 15, 2012)

Contacts

Primary ContactJianlin Huang, PhD
jianlin_h@163.com86 02085252194
Backup ContactGuihua Chen, PhD
zssyyuanzhangban@163.com86 02085252205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026